悦康药业：拟发行H股股票并在香港联合交易所有限公司上市

Core Viewpoint - The company plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its competitive edge and international brand image while diversifying its financing channels [1] Group 1 - The third meeting of the company's third board of directors will be held on December 4, 2025, to review the proposal for issuing H-shares [1] - The company aims to utilize international capital markets more effectively through this listing [1] - The move is expected to improve the company's overall competitiveness [1]